SCHEMBL4496788

SCHEMBL4496788

O=Cc1cc(-c2cccs2)sc1-c1cccs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.50
ERN1 O75460 6/20 0.49
KDM4E B2RXH2 3/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 2/20 0.38
LMNA P02545 3/20 0.38
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 2/20 0.38
GLA P06280 1/20 0.38
TP53 P04637 1/20 0.37
POLB P06746 1/20 0.37
HPGD P15428 1/20 0.37
NFKB1 P19838 1/20 0.37
MAPK1 P28482 1/20 0.37
CASP1 P29466 1/20 0.37
RAB9A P51151 1/20 0.37
CASP7 P55210 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL498578 0.87 DPP4 (0.45) DPP4ERN1KDM4EMAPTNPC1
SCHEMBL29839866 0.83 ERN1 (0.47) DPP4ERN1KDM4EMAPTNPC1
SCHEMBL975367 0.82 DPP4 (0.39) DPP4ERN1KDM4EMAPTNPC1
SCHEMBL499178 0.82 DPP4 (0.39) DPP4ERN1KDM4EMAPTNPC1
SCHEMBL16515585 0.82 DPP4 (0.50) DPP4ERN1KDM4EMAPTNPC1
SCHEMBL29419054 0.80 ERN1 (0.48) DPP4ERN1KDM4EMAPTNPC1
SCHEMBL14341162 0.79 DPP4 (0.37) DPP4ERN1KDM4EMAPTNPC1
SCHEMBL13757304 0.78 HCAR2 (0.49) DPP4KDM4EMAPTNPC1LMNA
SCHEMBL10070116 0.76 DPP4 (0.44) DPP4ERN1KDM4EMAPTNPC1
SCHEMBL14341160 0.76 DPP4 (0.39) DPP4ERN1KDM4EMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378058-B2 Conducting polymers and uses thereof AUCKLAND UNISERVICES LIMITED (NZ) 2013-02-19 US disclosed
US-8378058-B2 Conducting polymers and uses thereof AUCKLAND UNISERVICES LIMITED (NZ) 2013-02-19 US disclosed
US-8378058-B2 Conducting polymers and uses thereof AUCKLAND UNISERVICES LIMITED (NZ) 2013-02-19 US disclosed
US-20090215958-A1 CONDUCTING POLYMERS AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2009-08-27 US disclosed
US-20090215958-A1 CONDUCTING POLYMERS AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2009-08-27 US disclosed
US-20090215958-A1 CONDUCTING POLYMERS AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2009-08-27 US disclosed
EP-1594876-A4 CONDUCTING POLYMERS WITH PORPHYRIN CROSS-LINKERS UNIV WOLLONGONG (AU) 2008-07-09 EP disclosed
US-20070295398-A1 Conducting Polymers With Porphyrin Cross-Linkers WOLLONGONG, UNIVERSITY OF (AU) 2007-12-27 US disclosed
WO-2007018439-A1 CONDUCTING POLYMERS AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2007-02-15 WO disclosed
WO-2007018439-A1 CONDUCTING POLYMERS AND USES THEREOF AUCKLAND UNISERVICES LIMITED (NZ) 2007-02-15 WO disclosed
EP-1594876-A1 CONDUCTING POLYMERS WITH PORPHYRIN CROSS-LINKERS University of Wollongong (AU) 2005-11-16 EP disclosed
WO-2004067533-A1 CONDUCTING POLYMERS WITH PORPHYRIN CROSS-LINKERS UNIVERSITY OF WOLLONGONG (AU) 2004-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215958-A1 CONDUCTING POLYMERS AND USES THEREOF PIN1, PPIA, PARG DPP4 4681/4885ERN1 2632/4885KDM4E 4847/4885
US-20070295398-A1 Conducting Polymers With Porphyrin Cross-Linkers QPCT, LCP1, QPCTL DPP4 3662/4885ERN1 4786/4885KDM4E 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.